Blueshift Asset Management, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Blueshift Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$99.73 - $148.48 $235,761 - $351,006	-2,364 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$98.85 - $138.91 $1.26 Million - $1.77 Million	-12,735 Reduced 84.34%	2,364 $328,000
Q2 2021 Aug 13, 2021	BUY	$65.78 - $105.02 $993,212 - $1.59 Million	15,099 New	15,099 $1.47 Million
Q4 2020 Feb 12, 2021	SELL	$65.07 - $98.24 $276,742 - $417,814	-4,253 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$59.04 - $77.95 $279,318 - $368,781	-4,731 Reduced 52.66%	4,253 $276,000
Q2 2020 Aug 13, 2020	BUY	$29.01 - $74.23 $260,625 - $666,882	8,984 New	8,984 $657,000
Q4 2019 Feb 14, 2020	SELL	$40.86 - $57.65 $697,235 - $983,739	-17,064 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$37.38 - $49.47 $335,298 - $443,745	8,970 Added 110.82%	17,064 $712,000
Q2 2019 Aug 14, 2019	SELL	$39.79 - $67.01 $532,788 - $897,263	-13,390 Reduced 62.33%	8,094 $354,000
Q1 2019 May 14, 2019	BUY	$34.52 - $53.29 $455,733 - $703,534	13,202 Added 159.41%	21,484 $1.11 Million
Q4 2018 Feb 12, 2019	BUY	$29.75 - $42.9 $246,389 - $355,297	8,282 New	8,282 $306,000

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Blueshift Asset Management, LLC with notifications on news.